Novo Nordisk Releases Topline Results From Phase 3 REIMAGINE 5 and REDEFINE 9 Trials Of Once-Weekly Cagrisema (Cagrilintide and Semaglutide)
Novo Nordisk today announced topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema (cagrilintide and semaglutide), an investigational product, and Novo's next innovation in
Novo Nordisk tested a new medicine called CagriSema in two big trials. When a company shares positive study results, it hints the medicine might work well and could help their future.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.